Telomir Pharmaceuticals
Telomere-based therapies targeting age-related diseases by enhancing DNA protection and cell renewal.
| USD | 2021 | 2022 | 2023 | 2024 | 2026 |
|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 |
Source: Company filings or news article, Equity research estimates
Related Content
Telomir Pharmaceuticals focuses on developing therapies that protect stem cells by elongating and stimulating telomeres, crucial for DNA protection and self-renewal. The company operates in the biotechnology sector, targeting age-related diseases through telomere-based treatments. Its business model revolves around research and development, leveraging decades of expertise in clinical, scientific, and regulatory fields. Revenue is generated through partnerships and potential commercialization of groundbreaking treatments. The management team brings a wealth of experience, aiming to advance healthcare and change the future of medicine.
Keywords: telomeres, stem cells, DNA protection, age-related diseases, biotechnology, healthcare, research, development, treatments, medicine.